期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

E-钙黏蛋白在三阴性乳腺癌组织中的表达 被引量：3

Expression of E-cadherin in the Triple Negative Breast Cancer
下载PDF
导出
摘要 目的检测E-钙黏蛋白(E-cad)在三阴性乳腺癌(TNBC)组织中的表达,探讨其评估预后的价值。方法采用免疫组化方法检测经手术病理确诊的147例TNBC患者的E-cad的表达情况。结果 TNBC组织中E-cad的阳性率为32%(47/147)。E-cad阳性表达与肿块大小、组织学分级、淋巴结转移均有关(P均<0.05)。E-cad阴性患者的5 a总生存率和无病生存率均低于E-cad阳性患者(61%vs 89%,27%vs 65%,P均<0.05)。结论 TNBC中E-cad阳性者预后好,上调E-cad表达可能成为TNBC新的治疗手段。 Objective To investigate the expression and the prognostic value of E-cadherin （E-cad）in the triple negative breast cancer （TNBC）. Methods Immunohistochemical staining was used to detect the expression of E- cad in the 147 cases of TNBC. Results The positive rate of E-cad expression was 32% （47/147） in the TNBC. E- cad was significantly correlated with the tumor volume, histological grade and lymph node metastasis （ P 〈 0.05 ）. The follow-up showed that the 5-year disease-free survival and overall survival rates of the patients with the negative E-cad expression were lower than those of the patients with positive E-cad expression （61% vs 89% , 27% vs 65% ,P 〈 0.05）. Conclusion TNBC with positive E-cad has good prognosis, Up-regulation of E-cad may become a therapeutic tool for TNBC.
作者 孙弢 姚宇锋 龚建平 秦建伟 唐金海
机构地区 滁州市第一人民医院普外科 江苏省肿瘤医院普外科
出处 《肿瘤基础与临床》 2014年第1期8-10,共3页 journal of basic and clinical oncology
关键词 E-钙黏蛋白 乳腺肿瘤 预后 E-cadherin breast neoplasms prognosis
分类号 R737.9 [医药卫生—肿瘤] R730.23 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Singhai R,Patil VW,Jaiswal SR. E-Cadherin as a diagnostic biomarker in breast cancer[J].N Am J Med Sci,2011,(05):227-233.
  • 2Thiery JP. Epithelial-mesenchymal transitions in tumour progression[J].Nature Reviews Cancer,2002,(06):442-454.
  • 3Carey LA,Perou CM,Livasy CA. Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA:the Journal of the American Medical Association,2006,(21):2492-2502.
  • 4Rakha EA,El-Rehim DA,Paish C. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance[J].EUROPEAN JOURNAL OF CANCER,2006,(18):3149-3156.
  • 5Bauer KR,Brown M,Cress RD. Descriptive analysis of estrogen receptor (ER)-negative,progesterone receptor (PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a population-based study from the Californiacancer Registry[J].CANCER,2007,(09):1721-1728.
  • 6Tang D,Xu S,Zhang Q. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J].MEDICAL ONCOLOGY,2012,(02):526-533.
  • 7Kashiwagi S,Yashiro M,Takashima T. Significance of E-cadherin expression in triple-negative breast cancer[J].British Journal of Cancer,2010,(02):249-255.
  • 8Gould Rothberg BE,Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast:a systematic review and meta-analysis[J].Breast Cancer Research and Treatment,2006,(02):139-148.
  • 9Yang SZ,Kohno N,Kondo K. Adriamycin activates E-cadherin-mediated cell-cell adhesion in human breast cancer cells[J].International Journal of Oncology,1999,(06):1109-1115.
  • 10Turner JR,Torres CM,Wang HH. Preoperative chemoradiotherapy alters the expression and prognostic significance of adhesion molecules in Barrett\'s-associated adenocarcinoma[J].Human Pathology,2000,(03):347-353.

二级参考文献10

  • 1Baranwal S,Alahari SK.Molecular mechanisms controlling E-cadherin expression in breast cancer[J].Biochem Biophys Res Commun,2009,384(1):6-11.
  • 2Gloushankova NA.Changes in regulation of cell-cell adhesion during tumor transformtion[J].Biochemistry (Mosc),2008,73(7):742-750.
  • 3Cleton-Jansen AM,Moerland EW,Kuipers-Dijkshoom N J,et al.At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer[J].Genes Chromosomes Cancer,1994,9(2):101-107.
  • 4Shiozaki H,Oka H,Inoue M,et al.E-cadherin mediated adhesion system in cancer cells[J].Cancer,1996,77(8):1605-1613.
  • 5Mohammadizadeh F,Ghasemibasir H,Rajabi P,et al.Correlation of Ecadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma[J].Cancer Biomark,2009,5(1):18.
  • 6Kowalski PJ,Rubin MA,Kleer CG.E-cadherin expression in primary carcinomas of the breast and its distant metastases[J].Breast Cancer Res,2003,5(6):R217-R222.
  • 7Wong AS,Gumbiner BM.Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin[J].J Cell Biol,2003,161(6):1191-1203.
  • 8Lester RD,Jo M,Montel V,et al.uPAR induces epithelial-mesencbymal transition in hypoxic breast cancer cells[J].J Cell Biol,2007,178(3):425-436.
  • 9Arima Y,Inoue Y,Shibata T,et al.Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition[J].Cancer Res,2008,68(13):5104-5112.
  • 10李嗣杰,贾泓瑶,韩冰,吴迪,付彤.信号转导及转录活化因子3蛋白在乳腺癌组织中的表达及其临床意义[J].吉林大学学报（医学版）,2011,37(1):72-75. 被引量：2

共引文献1

同被引文献21

  • 1Savci-Heijink CD, Halfwerk H, Hooijer GK, et al.Retrospective analysis of metastatic behaviour of breast cancersubtypes [ J ]. Breast Cancer Res Treat, 2015,150 (3 ):547-557.
  • 2Goldhirsch A, Winer EP, Coates AS, et al. Personalizing thetreatment of women with early breast cancer : highlights of the StGallen International Expert Consensus on the Primary Therapyof Early Breast Cancer 2013 [ J]. Ann Oncol,2013,24 (9):2206-2223.
  • 3Paredes J, Figueiredo J, Albergaria A, et al. Epithelial E- andP-cadherins : role and clinical significance in cancer [ J ].Biochim Biophys Acta, 2012,1826 :297-311.
  • 4Ye Y, Tian H, Lange AR, et al. The genesis and uniqueproperties of the lymphovascular tumor embolus are because ofcaipain-regulated proteolysis of E-cadherin [ J ]. Oncogene,2013,32(13):1702-1713.
  • 5Guo J, Liu Z,Zhang G, et al. Efficiency and safety oftrastuzumab plus chemotherapy in Her-2 overexpressingmetastatic breast cancer patients [ J]. Chinese-German J ClinOnwl, 2014,13(12) :555-559.
  • 6Mahler-Araujo B, Savage K, Parry S, et al. Reduction ofE-cadherin expression is associated with non-lobular breastcarcinomas of basal-like and triple negative phenotype[ J]. JClin Pathol, 2008,61(5) :615-620.
  • 7Wolff AC, Hammond ME, Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer : American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update[ J]. JClin Oncol, 2013,31(31):39974013.
  • 8Goldhirsch A, Wood WC, Coates AS, et al. Strategies forsubtypes—dealing with the diversity of breast cancer : highlightsof the St. Gallen International Expert Consensus on the PrimaryTherapy of Early Breast Cancer 2011 [ J] . Ann Oncol,2011,22(8) :1736-1747.
  • 9Bauer KR, Brown M, Cress RD, et al. Descriptive analysis ofestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2 - negative invasive breast cancer, the so-called triple-negative phenotype[ J]. Cancer, 2007,109 (9):1721-1728.
  • 10Thiery JP. Epithelial-mesenchymal transitions in tumourprogression[ J] . Nat Rev Cancer, 2002,2(6) ;442-454.

引证文献3

二级引证文献20

肿瘤基础与临床
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部